Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Market Cap	98.23M 10.38M 8.94M 8.22M 7.73M 14.41M 982M 14.68M 96.95M 37.85M 482M 38.94M 38.1M 1.66B	P/E Ratio 2026 *	-0.87x	P/E Ratio 2027 *	-1.18x
Enterprise Value	134M 14.18M 12.21M 11.24M 10.56M 19.69M 1.34B 20.06M 132M 51.72M 658M 53.21M 52.07M 2.27B	EV / Sales 2026 *	-	EV / Sales 2027 *	27.2x
Free-Float	51.56%	Yield 2026 *	-	Yield 2027 *	-

06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-13	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI
03-10	Lifecare receives regulatory feedback on first-in-human application	RE
03-09	Lifecare ASA Receives Regulatory Feedback on First-in-Human Application	CI
03-05	Lifecare ASA Confirms 12-Week Implant Stability Under Real-Life Conditions And Reduces Durability Risk Ahead Of First-In-Human Study	CI

06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU
06-10	Lifecare completes first six-month implant evaluation with continued functionality and no adverse biological response	AQ
06-01	Lifecare ASA: Commencement of the Exercise Period for Warrants Series 2 issued in connection with the Rights Issue	PU
05-19	Lifecare ASA: Mandatory notification of trade	PU

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	2020-09-06
Petter Nielsen DFI	Director of Finance/CFO	-	2026-03-31
Torsten Ernst PRN	Corporate Officer/Principal	-	2024-02-29

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	2020-06-25
Morten Foros Krohnstad CHM	Chairman	-	2021-05-07
Lutz Heinemann BRD	Director/Board Member	-	2020-11-19

Lifecare AS Stock Oslo Bors

Stocks

NO0010591191

Biotechnology & Medical Research

Valuation: Lifecare AS

Latest news : Lifecare AS

Last Transcript: Lifecare AS

Analysts' recommendations: Lifecare AS

Press Releases: Lifecare AS

News in other languages: Lifecare AS

Managers and Directors: Lifecare AS

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE AS	-.--%	-4.31%	-	-	9.7M
LONZA GROUP AG	-0.12%	+1.04%	-13.08%	-12.43%	43.58B
REVOLUTION MEDICINES, INC.	-2.17%	+5.45%	+285.76%	+522.83%	34.03B
IQVIA HOLDINGS INC.	+0.44%	-2.46%	+14.20%	-17.35%	29.77B
BEONE MEDICINES AG	-1.60%	-2.54%	-2.12%	+31.28%	29.82B
CELLTRION, INC.	-0.29%	+9.47%	+13.95%	+21.93%	25.42B
ASCENDIS PHARMA A/S	+3.54%	+12.34%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-1.26%	+0.81%	+54.77%	+109.24%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.33%	+3.98%	+3.91%	12.85B
IONIS PHARMACEUTICALS, INC.	-1.18%	-0.61%	+105.37%	+75.32%	12.22B
Average	-0.39%	+2.03%	+57.85%	+91.84%	23.88B
Weighted average by Cap.	-0.58%	+2.02%	+59.38%	+102.72%

	2026 *	2027 *
Net sales	-	5M 528K 455K 418K 393K 734K 49.97M 747K 4.93M 1.93M 24.52M 1.98M 1.94M 84.52M
Net income	-86M -9.09M -7.82M -7.2M -6.77M -12.62M -860M -12.85M -84.88M -33.13M -422M -34.09M -33.36M -1.45B	-82M -8.66M -7.46M -6.86M -6.45M -12.03M -820M -12.25M -80.93M -31.59M -402M -32.51M -31.81M -1.39B
Net Debt	36M 3.8M 3.27M 3.01M 2.83M 5.28M 360M 5.38M 35.53M 13.87M 177M 14.27M 13.96M 609M	38M 4.01M 3.46M 3.18M 2.99M 5.57M 380M 5.68M 37.5M 14.64M 186M 15.06M 14.74M 642M